Reconfiguring Drug Discovery Through Innovative Partnerships By Dr Robert Grundy, Iain James, Chas Bountra and Timothy Harrison Attrition rates in drug discovery and development remain stubbornly high, despite large investments by the pharmaceutical industry. The cost of developing a new drug has been estimated at between $1.3 billion… Read More
By Dr Scott R. Burger, Louis Juliano, and Dr Wenshi Wang For more than two decades, the biotechnology and pharmaceutical industries have been working to unlock the great potential of cell therapy, which uses products composed of living, functional cells to mediate the therapeutic effect. Read More
Targeted Chemical Libraries: The keys to unlock the ubiquitin system By Dr Jason Brown and Dr J. Mark Treherne Is novel chemistry the final frontier for ubiquitin system drug discovery? Although the widespread use of target-focused libraries… Read More
Oncology Target Discovery by RNAi: The past, present, and future perspectives By Dr Hakim Djaballah and Bhavneet Bhinder Despite an investment of billions of US dollars in the search of novel therapies, cancer still remains the leading cause of death in the world. This emphasises the need… Read More
Could The Keys To Precision & Personalised Medicine Be Rooted In Predictive Safety & Research Methods? By Robert G. Hunter To meet the massive challenges of future healthcare, perhaps no two facets hold greater promise than biomarkers for precision medicine and systems biology for personalised patient care. Read More
Long Live Peptides – Evolution of peptide half-life extension technologies and emerging hybrid approaches By Dr Ronald V. Swanson Among therapeutic modalities, peptides occupy a middle ground between traditional ‘small molecule’ drugs and the larger injectable biologics, not fitting comfortably into either category. Read More
The Current Status of Non-Biopharma Drug Discovery By Dr John Comley Screening centres in academic institutions and non-profit organisations have, over the past decade, become an established mechanism to exploit novel targets and neglected diseases and to identify chemical probes. Where centres have… Read More
Developing The First Treatment For Acute Kidney Injury By Tim Knotnerus Acute Kidney Injury (AKI) is a devastating disease characterised by a rapid loss of kidney function resulting in inability to maintain fluid, electrolyte and acidbase balance. AKI is particularly common in patients admitted to the Intensive Care… Read More
How Digital Innovation and Collaboration Is Driving a Global Demand for Effective Reporting in Research Funding By Frances Buck The UK, Europe and the United States are world leaders in research and innovation, with their researchers making vast contributions to global knowledge. They have world-leading universities, research… Read More
Building New Models of Drug Discovery in Europe – The Innovative Medicines Initiative By Dr Angela Wittelsberger, Dr Hugh Laverty and Dr Michel Goldman The discovery and development of a new medicine is time-consuming, risky and expensive. It often takes 10-15 years and an investment of on average… Read More
Collaboration For Innovation Is The New Mantra For The Pharmaceutical Industry By Professor Jackie Hunter In order to maintain a flow of innovative medicines there is a growing realisation that companies cannot allow the status quo to remain as it is and the need to identify sources of… Read More
By Dr John Comley 3D cell culture has the potential to deliver higher quality culture information that is more representative of tissue morphology and predictive of drug responses in vivo. Three years ago we concluded in DDW that 3D cell culture… Read More
More Than Genes and Cells: Drug Discovery in the Extracellular Matrix (ECM) By Dr William Bains Drug discovery in the last few decades has focused on the cellular and genetic mechanisms of disease. This has been very successful in cancer, which is a disease of somatic genetics, and… Read More
Stem Cell Banking In Support of Drug Discovery By Dr Thomas J Novak, Dr Uta Grieshammer, Dr Michael Yaffe and Dr Steve Madore The discovery by Yamanaka and Thomson in 2007 that human somatic cells can be reprogrammed to a pluripotent state (ie, induced pluripotent stem cells, iPSCs)… Read More
Large-Scale Expansion of Stem Cells For Therapy and Screening By Dr Y. John Shyu, Dr Katherine E. Strathearn and Dr Richard M. Eglen Recently, pre-clinical and clinical studies of stem cells in regenerative medicine have demonstrated great promise as treatments for various diseases. Their ability to self-renew and… Read More
The Drug Repositioning Revolution: Rescuing & Repurposing Drugs By Dr Monika Green and Dr Kate Hudson-Farmer Cost containment and improving ways of treating people are key drivers for healthcare systems. Unfortunately, these do not often go hand in hand. Finding novel therapeutics with enhanced efficacy is both time… Read More